placebo

Vivus Adds 12% in Early Trading on Qnexa Study Results

blood pressure, clinical study, diet, drug, fat, health, lipid, medical, medication, obesity, pharma, pill, placebo, qnexa, trade, vivus, vvus, weight loss

Vivus (VVUS) is up by double digits in early trading, after it says long-term data demonstrated patients treated with the investigational drug QNEXA for two years showed reductions in blood pressure and the use of antihypertensive

By FNNO Staff
fnnonline@gmail.com

Repligen Reports Disappointing Bi-Polar Drug Results, Down Over 25%

The company noted that the 50 patients enrolled through academic medical centers did show a clinically meaningful improvement, while the 125 patients enrolled at the commercial clinical trial sites did not, and it would look in to

The stock is trading down 28% at $3.53 per share.

bipolar, clinical, disorder, drug, healthcare, medical, medicine, mental health, nasdaq, placebo, repligen, rgen, shares, stock, trial, uridine

Repligen Corporation (NASDAQ:RGEN) said Monday that a mid-stage clinical trial for its bi-polar drug RG2417, an oral form of uridine, did not significantly improve symptoms compared to a placebo over an eight-week period.

By Stephanie Shyu
sshyu@fnno.com

Vertex Pharmaceuticals Shares Up Over 14% On Positive Clinical Trial Results

The trial found patients taking the drug experienced a 17% relative improvement in their ability to force air out of their lungs in one second, a common measure of success in treating lung disease, compared with those on a placebo

Vertex's trial would have been deemed a success if it had delivered just a 4.5% improvement in the lung function test.

analyst, clinical, cystic fibrosis, disease, drugs, financial, health, healthcare, lungs, market, marketing, medical, medicine, nasdaq, patients, pharma, placebo, regulatory approval, shares, stock, trial, Vertex, vrtx, vx770

Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) are up over 14% today, after it announced positive clinical trial results for its cystic fibrosis fighting drug VX-770.

By Mathieu Lloyd
mlloyd@fnno.com

Teva Reports Positive Study Results for MS Treatment, Advanc

teva, pharmaceutical, active, biotech, acti, clinical, allegro, study, multiple, sclerosis, ms, patients, drug, laquinimod, placebo, relapse, remission, expanded, disability, severity, scale, edss, fnn

By Anonymous

Latest News from FNNO

Earnings Flashback: Since Reporting Quar...

18 days ago, on July 8th, 2014, Bob Evans Farms (NASDAQ:BOBE) reported its earnings. A ...

Earnings Flashback: Since Reporting Quar...

11 days ago, on July 15th, 2014, CSX (NYSE:CSX) reported its earnings. Analysts, on av ...

Dover Earnings Review: 9 Days after Anno...

When Dover (NYSE:DOV) reported earnings 9 days ago on July 17th, 2014, analysts, on ave ...

Earnings Look Back: Autoliv Is Down 0.3%...

A week ago on July 18th, 2014 Autoliv (NYSE:ALV) reported earnings and analysts, on ave ...

Earnings Flashback: Since Reporting Quar...

A week ago on July 18th, 2014 Kansas City Southern (NYSE:KSU) reported earnings and ana ...

Cytec Industries Earnings Hindsight: Up ...

When Cytec Industries (NYSE:CYT) reported earnings a week ago on July 17th, 2014, analy ...

Novartis Earnings Hindsight: Down 0.1% i...

When Novartis (NYSE:NVS) reported earnings 9 days ago on July 17th, 2014, analysts, on ...

Post Earnings Update: AAR Has Climbed 4....

11 days ago, on July 15th, 2014, AAR (NYSE:AIR) reported its earnings. Analysts, on av ...

Most Popular Video News